Phaseline

Companies › CyanVac

CyanVac: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CVM150
Live PIV5-based mumps virus vaccine expressing mumps F and HN proteins
–Phase 1MumpsDec 2027
CVM26
Live attenuated mumps virus vaccine with V and SH protein expression removed
–Phase 1MumpsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06967181CVM150Phase 1MumpsInfectious diseaseDec 2027
NCT06967181CVM26Phase 1MumpsInfectious diseaseDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.